Monthly Archives: October 2012

Use of Medical Food Theramine® Found to be Safer and Less Costly Than NSAIDs for Pain Treatment in Elderly Patients

Pharmacoeconomic Analysis Examines the Additional Cost to PreventGastrointestinal Side Effects and Complications Theramine® Lowered C-reactive protein (CRP) in Clinical Trial Los Angeles, October 23, 2012 – Medical food Theramine® should be the preferred treatment for pain when compared to NSAIDs (non-steroidal anti-inflammatory drugs) in elderly patients 65 years and older, according to a pharmacoeconomic analysis conducted by Targeted Medical Pharma, Inc. (OTCQB: TRGM) (OTCBB: TRGM) published in the May issue of the Journal of Pharmacy Research. The scientific economic paper, “Theramine (A Medical Food) Versus Continue reading →

Clinical Trials Show Theramine® is Effective at Reducing Inflammation Associated with Chronic Back Pain

Los Angeles, October 18, 2012 – Targeted Medical Pharma, Inc. (OTCQB: TRGM) (OTCBB: TRGM) reported today that the prescription only medical food Theramine is an effective medication for reducing inflammation associated with pain syndromes. Theramine has been the subject of two large double-blind, randomized, multi-center trials, which compared Theramine to low dose naproxen and ibuprofen. 256 subjects participated in the two studies across 20 independent sites that were randomized for treatment to receive Theramine alone (two capsules twice daily), NSAID or a combination of both. Continue reading →

Targeted Medical Pharma Commences Public Trading of Its Securities

Shares Begin Trading Over-the-Counter Under Symbol “TRGM” Los Angeles, October, 12, 2012 – Targeted Medical Pharma, Inc., a specialty pharmaceutical company that develops and distributes prescription medical foods to physicians, pharmacies and skilled nursing facilities, today announced that effective today, its common shares will be trading over-the-counter under the symbol “TRGM” on OTC Market Group’s OTCQB market and the Over-the-Counter Bulletin Board (OTCBB). The company’s publicly traded status follows FINRA’s approval of its 15c2-11 filing. “We are very excited to begin the next phase of Continue reading →